ALX ONCOLOGY HOLDINGS INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.61 USD | -1.48% |
|
+17.60% | +12.39% |
| 04-18 | Alx Oncology Holdings Insider Sold Shares Worth $710,195, According to a Recent SEC Filing | MT |
| 04-10 | ALX Oncology Reports Positive Data From Ongoing Phase 1/2 Trial of Evorpacept | MT |
Chart calendar ALX Oncology Holdings Inc.
70e800b0b7.Ce3hHjZWq70csi4DbmCrESUR7si48L5yr0Bgv18I3mM.fp6vTw8u_P9L2lowNy7hJUY8hprdl9MI_Tcl2AdxrA1QoNhUYTDCjkPXSQ~ffca5de74189f89b1d61dc61e095e209
Upcoming events on ALX Oncology Holdings Inc.
Past events on ALX Oncology Holdings Inc.
| 09/04/2024 22:30 | American Association for Cancer Research Meeting - Abstract No: CT037 |
| 08/04/2024 17:30 | American Association for Cancer Research Meeting - Abstract No: CT060 |
| 07/03/2024 21:03 | Q4 2023 Earnings Release |
| 09/01/2024 00:30 | JPMorgan Healthcare Conference |
| 28/11/2023 21:30 | Piper Sandler Healthcare Conference |
| 14/11/2023 15:00 | Jefferies London Healthcare Conference |
| 13/11/2023 21:05 | Q3 2023 Earnings Release |
| 08/11/2023 18:30 | UBS BioPharma Conference |
| 03/10/2023 13:00 | ASPEN-06 Phase 2 Clinical Trial Results Call |
| 26/09/2023 14:20 | Cantor Global Healthcare Conference |
| 11/09/2023 19:30 | H.C. Wainwright Global Investment Conference |
| 09/08/2023 21:01 | Q2 2023 Earnings Release |
| 16/06/2023 21:00 | Annual General Meeting |
| 11/05/2023 21:01 | Q1 2023 Earnings Release |
| 09/03/2023 21:01 | Q4 2022 Earnings Release |
| 10/01/2023 18:30 | JP Morgan Healthcare Conference |
| 13/12/2022 12:30 | American Society of Hematology Meeting |
| 12/12/2022 | American Society of Hematology Meeting - Publication No. 4076 |
| 29/11/2022 14:00 | Piper Sandler Healthcare Conference |
| 17/11/2022 14:40 | Jefferies London Healthcare Conference |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 4,80 | 1,18 1,11 6.22% | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 |
|
EBITDA Million USD | Released Forecast Spread | 0,00 | -43,5 -37,8 -14.98% | -83,5 -80,2 -4.12% | -127 -121 -5.09% | -169 -126 -34.78% | -167 |
|
EBIT Million USD | Released Forecast Spread | 0,00 | -43,7 -38,0 -14.84% | -83,6 -80,6 -3.67% | -127 -130 1.76% | -170 -166 -2.33% | -173 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | 0,00 | -45,5 -39,4 -15.53% | -83,5 -79,9 -4.49% | -123 -131 5.61% | -161 -158 -1.52% | -165 |
|
Net income Million USD | Released Forecast Spread | 0,00 | -45,7 -41,9 -9.25% | -83,5 -79,9 -4.46% | -123 -131 5.59% | -161 -161 0.35% | -173 |
|
EPS USD | Released Forecast Spread | -1,15 | -2,76 -1,87 -47.99% | -2,07 -1,97 -5.23% | -3,03 -3,13 3.23% | -3,74 -3,52 -6.32% | -3,27 |
| Announcement Date | 05/05/20 | 18/03/21 | 28/02/22 | 09/03/23 | 07/03/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
|
EBITDA Million USD | Released Forecast Spread | -33,7 -22,7 -48.48% | -36,6 -33,3 -9.87% | -32,1 -38,7 17.08% | -35,4 | -39,6 | -48,2 | -43,0 | |||||||
|
EBIT Million USD | Released Forecast Spread | -28,5 -26,7 -6.77% | -24,7 -31,0 20.04% | -33,8 -26,1 -29.26% | -36,7 -32,8 -11.95% | -32,2 -37,0 12.81% | -32,2 -33,4 3.54% | -36,8 -36,0 -2.26% | -53,3 -36,5 -45.84% | -48,0 -44,2 -8.74% | -42,5 | -42,7 | -44,1 | -43,6 | -41,6 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -28,5 -25,6 -11.13% | -24,5 -31,1 20.99% | -32,9 -26,4 -24.62% | -35,3 -33,4 -5.8% | -30,6 -37,9 19.05% | -30,2 -34,7 13.01% | -34,2 -35,3 3.14% | -51,0 -35,4 -44.09% | -45,5 -42,8 -6.25% | -42,2 | -41,2 | -41,0 | -41,0 | -40,3 |
|
Net income Million USD | Released Forecast Spread | -28,4 -25,6 -11.05% | -24,5 -31,0 20.96% | -32,9 -26,7 -23.14% | -35,3 -33,5 -5.31% | -30,7 -37,9 18.94% | -30,2 -35,8 15.63% | -34,2 -36,0 5.15% | -51,0 -36,5 -39.66% | -45,5 -44,6 -1.87% | -43,6 | -43,2 | -43,2 | -43,4 | -40,3 |
|
EPS USD | Released Forecast Spread | -0,70 -0,62 -13.25% | -0,60 -0,71 15.69% | -0,81 -0,63 -27.9% | -0,87 -0,79 -9.67% | -0,75 -0,90 17% | -0,74 -0,82 9.69% | -0,84 -0,87 3.27% | -1,24 -0,87 -42.31% | -0,93 -0,86 -8.1% | -0,84 | -0,84 | -0,81 | -0,80 | -0,76 |
| Announcement Date | 28/02/22 | 09/05/22 | 08/08/22 | 08/11/22 | 09/03/23 | 11/05/23 | 10/08/23 | 13/11/23 | 07/03/24 | - | - | - | - | - |
More events
Past sector events for ALX Oncology Holdings Inc.
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- ALXO Stock
- Calendar ALX Oncology Holdings Inc.
